-

11:01:37 AM

AMGN Stock News

AMGN - AMGEN Inc.

01/20/22 4:30 AM

Nasdaq : AMGN

LUMAKRAS® (SOTORASIB) RECEIVES APPROVAL IN JAPAN FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER

Amgen (NASDAQ: AMGN) today announced that LUMAKRAS ® (sotorasib) has been approved in Japan for the treatment of KRAS G12C-mutated positive, unresectable, advanced and/or recurrent non-small cell lung cancer (NSCLC) that has progressed after

RHEA-AI

neutral

01/13/22 7:00 AM

Nasdaq : AMGN

TEZSPIRE™ (TEZEPELUMAB-EKKO) NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF SEVERE ASTHMA

Amgen (NASDAQ:AMGN) and AstraZeneca today announced TEZSPIRE™ (tezepelumab-ekko) is now available for shipment to wholesalers in the U.S. TEZSPIRE was approved by the U.S. Food and Drug Administration (FDA) on Dec. 17, 2021 for the add-on

RHEA-AI

very negative

01/11/22 9:00 AM

Nasdaq : AMGN

AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO IDENTIFY NOVEL RNA DEGRADER SMALL MOLECULE THERAPEUTICS

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a range of difficult-to-drug targets in multiple therapeutic

RHEA-AI

neutral

01/10/22 4:00 PM

Nasdaq : AMGN

AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE THAT KARMA BIOTECHNOLOGIES WILL RECEIVE THE SECOND AMGEN GOLDEN TICKET

Amgen (NASDAQ:AMGN) and BioLabs LA at the Lundquist Institute today announced that Karma Biotechnologies has been awarded the second Amgen Golden Ticket in Southern California. Karma Biotechnologies will receive one year of lab space at BioLabs

RHEA-AI

very positive

01/10/22 12:00 AM

Nasdaq : AMGN

EUROPEAN COMMISSION APPROVES LUMYKRAS® (SOTORASIB) FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER

Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted conditional marketing authorization for LUMYKRAS ® (sotorasib), a first-in-class KRAS G12C inhibitor, for the treatment of adults with advanced non-small cell lung

RHEA-AI

positive

01/06/22 4:00 PM

Nasdaq : AMGN

conferences

AMGEN TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will virtually present at the 40 th Annual J.P. Morgan Healthcare Conference at 11:15 a.m. ET on Tuesday, Jan. 11, 2022. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference. Live

RHEA-AI

neutral

01/06/22 9:00 AM

Nasdaq : AMGN

Amgen and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement

Amgen and Generate Biomedicines today announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities. As part of the research collaboration, Amgen will pay $50 million in upfront funding for the initial five...

RHEA-AI

neutral

12/23/21 4:00 PM

Nasdaq : AMGN

conferences

AMGEN TO PRESENT AT THE GOLDMAN SACHS 14TH ANNUAL HEALTHCARE CEOS UNSCRIPTED CONFERENCE

Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference at 1:00 p.m. ET on Thursday, Jan. 6, 2022. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference.

RHEA-AI

neutral

12/20/21 4:25 PM

Nasdaq : AMGN

fda approval

FDA APPROVES OTEZLA® (APREMILAST) FOR THE TREATMENT OF ADULT PATIENTS WITH PLAQUE PSORIASIS, REGARDLESS OF SEVERITY LEVEL

Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla ® (apremilast) for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. With this

RHEA-AI

neutral

12/17/21 4:30 PM

Nasdaq : AMGN

fda approval

FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Amgen and AstraZeneca's Tezspire ™ (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

AMGN Data:

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.amgen.com
CeoRobert Bradway
Security nameAMGEN Inc.
Issue typecs
SectorManufacturing
Sic code2836
Employees24300
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address1 Amgen Center Dr
StateCalifornia
CityThousand Oaks
Zip91320-1799
CountryUS
Phone18054471000

AMGN Description:

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.